Company Long-Term Loans and Borrowings: Neurocrine Biosciences Inc (NBIX)

Brandmark of Neurocrine Corp (NBIX)

Geopolitical instability and the disruption of raw material supply chains are hindering the development of neurological drugs. The long-term liabilities of Neurocrine Biosciences (NBIX) demonstrate debt dynamics where 0.39 is the current level of the indicator. Business resilience is based on inelastic demand and the success of Ingrezza, while the high reputation of Kevin Gorman's team and the development of the R&D portfolio strengthen investor confidence.

Neurocrine (NBIX) Company Long-Term Debt: for the period 07/04/2022 - 11/01/2026

Neurocrine Biosciences Inc - analytical breakdowns and key metrics (NBIX)

- market price and analyst price targets:
Stock Price neurocrine.com|NBIX - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Neurocrine Biosciences|NBIX - Total Company Value
- book capitalization information:
Net Asset Value per Share Neurocrine Biosciences|NBIX - Company Book Value|Capitalization to Book Value Ratio neurocrine.com|NBIX - Company Total Assets
- debt level and financial liquidity data:
Debt to Capital Neurocrine Biosciences|NBIX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Neurocrine Corp|NBIX - Company Debts|Debt to Net Assets Ratio Neurocrine Biosciences|NBIX - Company Long-Term Debt|Short-Term Debt Neurocrine Biosciences|Quick Liquidity Indicator neurocrine.com
- earnings and market multiples details:
NBIX - Company Net Income
Analysis of all company metrics:neurocrine.com
Manufactured product of Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) maintains strong pricing power based on the uniqueness of its patents, ensuring a stable cash flow. By analyzing the value of the corporation's long-term loans and borrowings, an investor sees the current level of 0.39. This metric aggregates obligations with a maturity of over one year, reflecting the long-term debt load. A decrease in this indicator confirms a healthier balance sheet, although it may suggest a slowdown in business expansion.

Competitors of Neurocrine Biosciences (NBIX)

Company Long-Term Debts biogen.com BIIB|RGC - Company Long-Term Debt|Company Long-Term Loans and Borrowings AXSM (Axsome)|ACADIA Pharmaceuticals Inc (ACAD) - Company Long-Term Debt|Long-Term Debt Xenon Corp (XENE)|Company Long-Term Debt Viking Therapeutics|Company Long-Term Indebtedness SUPN (supernus.com)|Company Long-Term Debts CPRX|DNLI - Long-Term Debt|Harmony Pharma - Company Long-Term Liabilities|Company Long-Term Debts Biohaven Corp BHVN|AMLX - Company Long-Term Debt|Company Long-Term Loans and Borrowings TRVI (trevitherapeutics.com)|Praxis Precision Medicines, Inc. (PRAX) - Company Long-Term Debt|Long-Term Debt Anavex (AVXL)|CBLL (CeriBell Corp) - Company Long-Term Debts|Company Long-Term Liabilities prothena.com (PRTA)|Company Long-Term Debt Alector, Inc. (ALEC)|ANNX (annexonbio.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debts OMER (Omeros)|Long-Term Debt Volume Neurogene Inc (NGNE)|ACIU - Company Long-Term Debt|VYGR (Voyager Corp) - Company Long-Term Indebtedness|NMRA: Company Long-Term Debts|Long-Term Debt scilexholding.com (SCLX)|Company Long-Term Liabilities TVGN|ACOG: Company Long-Term Loans and Borrowings|Company Long-Term Debts CGTX|Company Long-Term Debt IKT (Inhibikase Pharma)|Company Long-Term Debts SAVA (Cassava Sciences, Inc.)|Long-Term Debt Volume Assertio Holdings (ASRT)|COYA - Company Long-Term Debt|Long-Term Debt Vistagen Therapeutics|ovidrx.com (OVID) - Company Long-Term Debt|ABOS - Long-Term Debt Volume|CRVO (CervoMed Inc.) - Company Long-Term Debts|Company Long-Term Liabilities Alterity Therapeutics Ltd (ATHE)|Company Long-Term Debts CLNN|Long-Term Debt Volume pepgen.com|Company Long-Term Debts JUNS (Jupiter Neurosciences Inc)|Relmada Corp (RLMD) - Long-Term Debt|ANVS - Company Long-Term Debt|GRCE (Grace Therapeutics, Inc.) - Company Long-Term Indebtedness|AIFF: Company Long-Term Debts|Company Long-Term Liabilities Klotho Neurosciences|NRSN (NeuroSense Therapeutics Ltd) - Company Long-Term Debts|Long-Term Debt Reviva Pharmaceuticals, Inc. RVPH|Company Long-Term Debt MetaVia Inc (MTVA)|Long-Term Debt Volume neuraxis.com|Company Long-Term Debt Helius Medical Technologies HSDT|PASG: Company Long-Term Indebtedness|Neuphoria - Company Long-Term Debts|NERV: Company Long-Term Debt|ATHA: Company Long-Term Debts|ADXN - Long-Term Debt Volume|Company Long-Term Liabilities ALZN|Company Long-Term Indebtedness CYCN (Cyclerion)|Company Long-Term Debt Protagenic Therapeutics (PTIX)|pasitheaclinics.com - Company Long-Term Indebtedness|Company Long-Term Debts CRGT (Cortigent)|avenuetx.com (ATXI) - Long-Term Debt|BCLI: Company Long-Term Liabilities|CARA - Company Long-Term Debts|Chromocell Therapeutics Corporation (CHRO) - Company Long-Term Debt|Eliem Therapeutics Inc. - Company Long-Term Loans and Borrowings|Company Long-Term Debt Intra-Cellular Therapies Inc.|Long-Term Debt longboardpharma.com LBPH|Company Long-Term Debt Marinus Pharmaceuticals, Inc. (MRNS)|NKGen Biotech Inc - Company Long-Term Indebtedness|Company Long-Term Debts NRBO (NeuroBo)|Sage Therapeutics Inc (SAGE) - Long-Term Debt|SNPX: Company Long-Term Liabilities|TRVN - Company Long-Term Debts|vigilneuro.com (VIGL) - Company Long-Term Debt|Anew Medical Inc. - Company Long-Term Loans and Borrowings|Company Long-Term Debt Cerevel